A Value-Driven Future Approach to Precision Medicine for Health Sustainability in New Zealand: A Perspective

The concept of personalized and precision medicine has its origins in the development of pharmacogenomic tools. The primary goal is to predict disease risk proactively, continually monitor human health status, and reduce the costs associated with large clinical trials by tailoring treatments on a personalized level. However, achieving a personalized ecosystem requires further advancements to enable real-time decision-making and accurate predictions of target medicines for the benefit of the community. Theranostic and companion diagnostics are essential tools for imaging diagnosis, drug delivery, and monitoring specific therapeutic responses. Pharmacogenomics and pharmacogenetic testing could hold the potential to determine the response to precisely administered therapeutics and identify adverse reactions. OMICS-based testing, along with sequencing and molecular docking platforms, shows promise in improving prediction capabilities. The reproducible pieces of evidence of precise standards are the pre-requisite to translating precision medicine for their effective use and implementing the policies could help serve the purpose. Scientific validity, research protocols, methods, and accurate references are crucial for regulating precision medicines.